FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:
	Estimated average burden
Filed nursuant to Section 16(a) of the Securities Evolution Act of 1934	hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ABEL DOUGLAS					2. Issuer Name and Ticker or Trading Symbol MANHATTAN PHARMACEUTICALS INC [MHAN]										k all applica Director	,	Perso	10% Ov	vner
(Last) (First) (Middle) C/O MANHATTAN PHARMACEUTICALS, INC. 48 WALL STREET, SUITE 1110				iC.	3. Date of Earliest Transaction (Month/Day/Year) 03/03/2010										below)	give title		Other (s below)	
(Street) NEW Y(Y State)	10005 (Zip)		4. If Ame	endment,	, Date	of Ori	iginal Fi	led (N	Month/D	ay/Year)		6. Indi Line) X	Form file	int/Group F ed by One F ed by More	Repor	ting Person	
1. Title of Security (Instr. 3) 2. Trans Date				2. Transac	action 2A. Deemed Execution Date,			Code (Instr. 5)			or 5. Amount of Securities Beneficially Owned Following					7. Nature of Indirect Beneficial Ownership			
Common Stock							Code	v	Amoun	ount (A) or (D)		ce	Reported Transactio (Instr. 3 ar	ion(s) ind 4)		D	(Instr. 4)		
Common	Otock		Table II - [f, or Bei				1		<u> </u>	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Code	5. Number 6. Dat Expire		Expiration Date S Month/Day/Year) D			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		ng	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exerc	cisable	Expi Date	iration	Title	Amount Number Shares						
Stock Options	\$0.17							((1)	03/2	5/2018	Common Stock	1,300,0	000		1,300,00	00	D	
Warrant	\$0.2							((2)	09/1	0/2013	Common Stock	24,00	00		24,000		D	
Stock Options	\$0.07	03/03/2010		A ⁽³⁾		50,000			(4)	03/0	2/2020	Common Stock	50,00	00	\$0	50,000		D	

Explanation of Responses:

- 1. The option vested as to 433,333 shares on March 25, 2008 and as to an additional 433,334 shares on March 25, 2009. The remaining 433,334 shares are scheduled to vest on March 25, 2010.
- $2. \ The \ warrants \ are \ exercisable \ immediately.$
- 3. On March 3, 2010, the reporting person was granted an option to purchase 50,000 shares of common stock of Manhattan Pharmaceuticals, Inc. under the 2003 Stock Option Plan.
- 4. The option is scheduled to vest (i) as to 16,667 shares on each of March 3, 2011 and March 3, 2012, and (ii) as to the remaining 16,666 shares on March 3, 2013.

Remarks:

<u>/s/ Douglas Abel</u> <u>03/10/2010</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.